Literature DB >> 14636958

Drug dependence and the endogenous opioid system.

Mirjam A F M Gerrits1, Heidi B M Lesscher, Jan M van Ree.   

Abstract

The discovery of endogenous opioids has markedly influenced the research on the biology of drug dependence. Evidence has been presented that these brain substances are self-administered by laboratory animals. This finding, among others, has led to the hypothesis that endogenous opioids are involved in reinforcing habits, including dependence on drugs of abuse. The course of drug dependence is presented as a continuum from no drug use via controlled use to an actual dependence on the drug. Specific brain opioid systems belonging to four conceptualized brain circuits are described to be involved during the different phases of the drug dependence continuum. More recent research to delineate the role of endogenous opioid systems in drug dependence has focussed on genetic research in humans and animals. Among others, the findings obtained from studies of opioid receptor and opioid peptide precursor knockout mice provided further support for a role of endogenous opioid systems in drug dependence, in agreement with previous pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636958     DOI: 10.1016/j.euroneuro.2003.08.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  19 in total

1.  Photoactivatable neuropeptides for spatiotemporally precise delivery of opioids in neural tissue.

Authors:  Matthew R Banghart; Bernardo L Sabatini
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

2.  Conditioned place preference induced by electrical stimulation of the insular cortex: effects of naloxone.

Authors:  Raquel García; María J Simón; Amadeo Puerto
Journal:  Exp Brain Res       Date:  2013-02-02       Impact factor: 1.972

3.  Gene expression profiling following short-term and long-term morphine exposure in mice uncovers genes involved in food intake.

Authors:  A Anghel; C A M Jamieson; X Ren; J Young; R Porche; E Ozigbo; D E Ghods; M L Lee; Y Liu; K Lutfy; T C Friedman
Journal:  Neuroscience       Date:  2010-02-06       Impact factor: 3.590

4.  Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.

Authors:  Marisa Roberto; George R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

Review 5.  Pain, nicotine, and smoking: research findings and mechanistic considerations.

Authors:  Joseph W Ditre; Thomas H Brandon; Emily L Zale; Mary M Meagher
Journal:  Psychol Bull       Date:  2011-11       Impact factor: 17.737

6.  Neuroanatomical distribution of μ-opioid receptor mRNA and binding in monogamous prairie voles (Microtus ochrogaster) and non-monogamous meadow voles (Microtus pennsylvanicus).

Authors:  K Inoue; J P Burkett; L J Young
Journal:  Neuroscience       Date:  2013-03-26       Impact factor: 3.590

Review 7.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

Review 8.  The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.

Authors:  James P Burkett; Larry J Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-11       Impact factor: 4.530

9.  Enhanced sensitivity to naltrexone-induced drinking suppression of fluid intake and sucrose consumption in maternally separated rats.

Authors:  Clifford C Michaels; Stephen G Holtzman
Journal:  Pharmacol Biochem Behav       Date:  2007-03-28       Impact factor: 3.533

10.  Ovarian steroids alter mu opioid receptor trafficking in hippocampal parvalbumin GABAergic interneurons.

Authors:  Annelyn Torres-Reveron; Tanya J Williams; Jeanette D Chapleau; Elizabeth M Waters; Bruce S McEwen; Carrie T Drake; Teresa A Milner
Journal:  Exp Neurol       Date:  2009-06-06       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.